✦ LIBER ✦

Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient

✍ Scribed by Pircher, A.; Manzl, C.; Fiegl, M.; Popper, H.; Pirker, R.; Hilbe, W.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9154 Clinical outcomes in patients with

✍ Paz-Ares, L.; Soulières, D.; Klughammer, B.; Melezínek, I.; Moecks, J.; Keil, L. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 69 KB

6522 POSTER EGFR mutations and response

✍ Crinó, L.; Ludovini, V.; Pistola, L.; Floriani, I.; Betti, M.; Chiari, R.; Giuff 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Response to pemetrexed rechallenge after

✍ Li, Shuai; Zhou, Fangyu; Ren, Shengxiang; Zhou, Caicun 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 772 KB

Primary resistance to epidermal growth f

✍ Lee, J. K.; Shin, J.- Y.; Kim, S.; Lee, S.; Park, C.; Kim, J.- Y.; Koh, Y.; Keam 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 215 KB

9000 ORAL Epidermal Growth Factor Recept

✍ O'Bvrne, K.; Paz-Ares, L.; Pereira, J.R.; von Pawel, J.; Ramlau, R.; Störkel, S. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

A phase II study of Erbitux (IMC-C225),

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 157 KB